mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 10, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2026

Conditions
Stage III Hepatocellular Cancer (CNLC Staging)
Interventions
DRUG

mFOLFOX7+Camrelizumab+Apatinib

"Drug: Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Drug: Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle. Drug: Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Drug: Camrelizumab 200mg infusion on D1 for every 21 days Drug: Apatinib 250mg,po,qd for every 21 days"

Trial Locations (1)

510000

RECRUITING

Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER